XNAS · GH
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Guardant Health, Inc. Common Stock

Guardant Health, Inc. Common Stock

SERVICES-MEDICAL LABORATORIES
$167.98

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is GH moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Guardant Health, Inc. Common Stock
SERVICES-MEDICAL LABORATORIES
Listed since
2018
Employees
3K
Country
US

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$167.98
Last session
Day high
$167.98
Last session
Day low
$167.98
Last session
Previous close
$167.98
52W high
$168.22
-0.14% from high
52W low
$127.24
99% of range
Market cap
$22.3B
EPS
$-3.3000
Shares out
132.6M
VWAP
$167.98
Last session
Price history computed in-house
1W
+12.57%
SMA 50 $141.63 · above
SMA 200 $141.63 · above
52W position 99%
Veridion warehouse edge

Warehouse intelligence for GH.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

GH insider activity

Guardant Health, Inc. Common Stock

Score
Coverage building
Pressure
Net selling
Filings
66
Buys / sells
4 / 62
Net value
-$59.6M
Insiders
15
Named filers
TM
Tariq Musa
Insider
Leadership
PS
POTTER MYRTLE S
Insider
Leadership
KK
Kalia Kumud
Insider
Leadership
Cluster

3 insiders bought in the last 90 days

Net pressure

Net selling: -$59.6M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-232026-06-22Tariq MusaInsidersell$131.161,95111,048$256KSEC Form 4
2026-06-232026-06-22POTTER MYRTLE SInsidersell$131.161,55620,971$204KSEC Form 4
2026-06-172026-06-15Kalia KumudInsidersell$129.8231441,414$41KSEC Form 4
2026-06-162026-06-16Tariq MusaInsidersell$130.191168,796$15KSEC Form 4
2026-06-162026-06-15Freeman ChrisInsidersell$129.8259461,101$77KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 61 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

GH contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GH in this window.
Lobbying spend

GH lobbying filings, year to date.

Registered lobbying filings matched to Guardant Health, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GH in this window.
Latest news · GH
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for GH.
Options
Sovereign unlock shows live options positioning for GH.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.